Jacobs Levy Equity Management, Inc Akebia Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,205,128 shares of AKBA stock, worth $3.69 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,205,128
Previous 1,579,355
23.69%
Holding current value
$3.69 Million
Previous $3.03 Million
44.66%
% of portfolio
0.02%
Previous 0.01%
Shares
33 transactions
Others Institutions Holding AKBA
# of Institutions
169Shares Held
105MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$44.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$35.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$24.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$18.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$17.6 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $563M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...